WO2014145493A1 - Radioactive substrates for aldehyde dehydrogenase - Google Patents
Radioactive substrates for aldehyde dehydrogenase Download PDFInfo
- Publication number
- WO2014145493A1 WO2014145493A1 PCT/US2014/030274 US2014030274W WO2014145493A1 WO 2014145493 A1 WO2014145493 A1 WO 2014145493A1 US 2014030274 W US2014030274 W US 2014030274W WO 2014145493 A1 WO2014145493 A1 WO 2014145493A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- cells
- aldh
- aryl
- detectable substrate
- Prior art date
Links
- 239000000758 substrate Substances 0.000 title claims abstract description 60
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 title abstract description 59
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 title abstract description 59
- 230000002285 radioactive Effects 0.000 title description 6
- 230000001809 detectable Effects 0.000 claims abstract description 40
- -1 -O-alkyl Chemical group 0.000 claims description 72
- 150000001875 compounds Chemical class 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 claims description 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 34
- 125000005418 aryl aryl group Chemical group 0.000 claims description 27
- 125000001424 substituent group Chemical group 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 25
- 150000002367 halogens Chemical class 0.000 claims description 25
- 125000003342 alkenyl group Chemical group 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 230000002401 inhibitory effect Effects 0.000 claims description 21
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 18
- 125000002944 cyanoaryl group Chemical group 0.000 claims description 14
- 125000004999 nitroaryl group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 102100014001 ABCB1 Human genes 0.000 claims description 11
- 102100002706 ABCG2 Human genes 0.000 claims description 11
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 11
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 101700062711 ALD1 Proteins 0.000 claims description 9
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 230000000875 corresponding Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 125000004450 alkenylene group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 5
- 230000035695 Efflux Effects 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 125000000732 arylene group Chemical group 0.000 claims description 3
- 125000005647 linker group Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 230000001747 exhibiting Effects 0.000 claims description 2
- 101700064591 DHAG Proteins 0.000 claims 6
- 101710029055 SAS2025 Proteins 0.000 claims 6
- 101700062802 adhE Proteins 0.000 claims 6
- 101700029304 dhaB Proteins 0.000 claims 6
- 101700081403 dhaQ Proteins 0.000 claims 6
- 101700055608 puuC Proteins 0.000 claims 6
- 201000011510 cancer Diseases 0.000 abstract description 19
- 238000003384 imaging method Methods 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract 1
- 210000004027 cells Anatomy 0.000 description 75
- 210000000130 stem cell Anatomy 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 17
- 239000011734 sodium Substances 0.000 description 15
- 150000001299 aldehydes Chemical class 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000012216 imaging agent Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000003550 marker Substances 0.000 description 9
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atoms Chemical group C* 0.000 description 8
- 0 *C(*)CNC(*)* Chemical compound *C(*)CNC(*)* 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 239000012131 assay buffer Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000006574 non-aromatic ring group Chemical group 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 229960001722 verapamil Drugs 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 4
- 102000014961 Protein Precursors Human genes 0.000 description 4
- 108010078762 Protein Precursors Proteins 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 125000004663 dialkyl amino group Chemical group 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003834 intracellular Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000006011 modification reaction Methods 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 238000002600 positron emission tomography Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 101710005854 ALD6 Proteins 0.000 description 3
- 101710036635 ALDH1A1 Proteins 0.000 description 3
- 102100017506 ALDH1A1 Human genes 0.000 description 3
- 101700015273 ALDH2 Proteins 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 3
- 210000001672 Ovary Anatomy 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 101700036425 aldH1 Proteins 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000002609 media Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 210000001124 Body Fluids Anatomy 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 210000000481 Breast Anatomy 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- 210000001072 Colon Anatomy 0.000 description 2
- ZIUSSTSXXLLKKK-HWUZOJPISA-N Curcumin Natural products C1=C(O)C(OC)=CC(\C=C\C(\O)=C/C(=O)/C=C/C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-HWUZOJPISA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 229940093915 Gynecological Organic acids Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 210000003128 Head Anatomy 0.000 description 2
- AIONOLUJZLIMTK-AWEZNQCLSA-N Hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000003739 Neck Anatomy 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 210000000496 Pancreas Anatomy 0.000 description 2
- 210000002307 Prostate Anatomy 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- JUVIOZPCNVVQFO-HBGVWJBISA-N Rotenone Natural products O([C@H](CC1=C2O3)C(C)=C)C1=CC=C2C(=O)[C@@H]1[C@H]3COC2=C1C=C(OC)C(OC)=C2 JUVIOZPCNVVQFO-HBGVWJBISA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 210000003932 Urinary Bladder Anatomy 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 230000001086 cytosolic Effects 0.000 description 2
- 230000001472 cytotoxic Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DBEYVIGIPJSTOR-FHWLQOOXSA-N fumitremorgin C Chemical compound O=C1[C@@H]2CCCN2C(=O)[C@@H]2CC(C3=CC=C(C=C3N3)OC)=C3[C@H](C=C(C)C)N21 DBEYVIGIPJSTOR-FHWLQOOXSA-N 0.000 description 2
- 125000005842 heteroatoms Chemical group 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001172 regenerating Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000006168 tricyclic group Chemical group 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- FUJICALGSOMFAM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-iodobenzoate Chemical compound C1=CC(I)=CC=C1C(=O)ON1C(=O)CCC1=O FUJICALGSOMFAM-UHFFFAOYSA-N 0.000 description 1
- LOYKOFHWTNBVBE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-tributylstannylbenzoate Chemical compound C1=CC([Sn](CCCC)(CCCC)CCCC)=CC=C1C(=O)ON1C(=O)CCC1=O LOYKOFHWTNBVBE-UHFFFAOYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- VJFDVDXXJRSPLZ-VIFPVBQESA-L (3S)-3-(1-carboxylatoethenoxy)cyclohepta-1,6-diene-1-carboxylate Chemical group [O-]C(=O)C(=C)O[C@H]1CCC=CC(C([O-])=O)=C1 VJFDVDXXJRSPLZ-VIFPVBQESA-L 0.000 description 1
- GVJFFQYXVOJXFI-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a,9,9a,10,10a-tetradecahydroanthracene Chemical group C1C2CCCCC2CC2C1CCCC2 GVJFFQYXVOJXFI-UHFFFAOYSA-N 0.000 description 1
- PNKWFQCOTNIHSE-UHFFFAOYSA-N 1,4$l^{2}-thiazinane Chemical group C1CSCC[N]1 PNKWFQCOTNIHSE-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- SFBMENHESNKIKS-UHFFFAOYSA-N 1-oxa-2,3-diazacyclopent-2-en-4-yne Chemical group O1N=NC#C1 SFBMENHESNKIKS-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- XQHYECQMLZJNSI-UHFFFAOYSA-N 2-amino-3,4-diethylbenzaldehyde Chemical compound CCC1=CC=C(C=O)C(N)=C1CC XQHYECQMLZJNSI-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- BCVIWCRZYPHHMQ-BTJKTKAUSA-N 4-amino-N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxybenzamide;(Z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 BCVIWCRZYPHHMQ-BTJKTKAUSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- SVJMLYUFVDMUHP-XIFFEERXSA-N 5-O-[3-(4,4-diphenylpiperidin-1-yl)propyl] 3-O-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OCCCN2CCC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 SVJMLYUFVDMUHP-XIFFEERXSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 229960005054 ACEPROMAZINE Drugs 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N Acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960004035 Acetophenazine maleate Drugs 0.000 description 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
- 241000269328 Amphibia Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000003373 Basosquamous Carcinoma Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- SZDNCLZGQKXXMM-UHFFFAOYSA-N CCOC(CN)[O](CC)CC Chemical compound CCOC(CN)[O](CC)CC SZDNCLZGQKXXMM-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229940109262 Curcumin Drugs 0.000 description 1
- KDUIUFJBNGTBMD-VXMYFEMYSA-N Cyclooctatetraene Chemical group C1=C\C=C/C=C\C=C1 KDUIUFJBNGTBMD-VXMYFEMYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N Dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 Dipyridamole Drugs 0.000 description 1
- 229960000220 Doxazosin Mesylate Drugs 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 101700051117 FUT1 Proteins 0.000 description 1
- 229960003064 Flavoxate Hydrochloride Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmin Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N Mepacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- FJLBFSROUSIWMA-UHFFFAOYSA-N Metyrapone Chemical compound C=1C=CN=CC=1C(C)(C)C(=O)C1=CC=CN=C1 FJLBFSROUSIWMA-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009905 Neurofibromatosis Diseases 0.000 description 1
- 229950010800 Niguldipine Drugs 0.000 description 1
- XEIWWWPDOUQNJF-UHFFFAOYSA-N O=CCNC(c1ccccc1)=O Chemical compound O=CCNC(c1ccccc1)=O XEIWWWPDOUQNJF-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- BTFMCMVEUCGQDX-UHFFFAOYSA-N Piperacetazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 BTFMCMVEUCGQDX-UHFFFAOYSA-N 0.000 description 1
- 229960004265 Piperacetazine Drugs 0.000 description 1
- 239000010103 Podophyllin Substances 0.000 description 1
- 229960001289 Prazosin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N Prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 229940079923 Quinacrine Drugs 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 206010038038 Rectal cancer Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N Reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229960002477 Riboflavin Drugs 0.000 description 1
- AUNGANRZJHBGPY-OUCADQQQSA-N Riboflavin Natural products OC[C@@H](O)[C@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-OUCADQQQSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940080817 Rotenone Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- PCTRYMLLRKWXGF-UHFFFAOYSA-N Tracazolate Chemical compound CCCCNC1=C(C(=O)OCC)C(C)=NC2=C1C=NN2CC PCTRYMLLRKWXGF-UHFFFAOYSA-N 0.000 description 1
- 229950002859 Tracazolate Drugs 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- 208000009999 Tuberous Sclerosis Diseases 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000008383 Wilms Tumor Diseases 0.000 description 1
- NUKVZKPNSKJGBK-SPIKMXEPSA-N acetophenazine dimaleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 NUKVZKPNSKJGBK-SPIKMXEPSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 201000003076 angiosarcoma Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- QJBRNNNJBVJKPK-UHFFFAOYSA-N but-1-en-3-yne Chemical group C=[C]C#C QJBRNNNJBVJKPK-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2S)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
- 229960002144 clebopride maleate Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008356 dextrose and sodium chloride injection Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- XOEVKNFZUQEERE-UHFFFAOYSA-N flavoxate hydrochloride Chemical compound Cl.C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 XOEVKNFZUQEERE-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000035168 lymphangiogenesis Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- YQNJWSFZVFLXKM-UHFFFAOYSA-N methylidenecyclopentane Chemical group [CH2]C1=CCCC1 YQNJWSFZVFLXKM-UHFFFAOYSA-N 0.000 description 1
- 229960004465 metyrapone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N silicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000000700 tracer Substances 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90203—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
Abstract
A detectable substrate for aldehyde dehydrogenase (ALDH) can include a radiolabel. When acted upon by ALDH in an ALDH-expressing cell, e.g., cancer cells, the radiolabeled substrate accumulates in the ALDH-expressing cell. ALDH-expressing cells can be distinguished by the accumulated radioactivity. When combined with suitable imaging technique, the detectable substrate can be used for in vivo imaging of cancer cells.
Description
RADIOACTIVE SUBSTRATES FOR ALDEHYDE DEHYDROGENASE
CROSS-REFERENCE TO RELATED APPLICATION This application claims the benefit of U.S. Provisional Application No. 61/791,272, filed March 15, 2013; which is incorporated herein by reference in its entirety.
BACKGROUND
Aldehyde dehydrogenase (ALDH) is an evolutionarily conserved enzyme with pyridine nucleotide dependent oxidoreductase activity that performs a variety of critical cellular processes. These include production of retinoic acid essential for mammalian development, metabolism of fats and amino acids, and detoxification of endogenous and exogenous sources of hazardous aldehyde byproducts. Twenty human ALDH genes have been identified and many of their functions are still unknown. For the past two decades ALDH has been studied as a potential universal marker for normal and cancer stem cells as certain isoenzymes of the ALDH superfamily have been identified as key elements of these cells. For example, Aldhlal and Aldh3al have been implicated in the protection of stem cells from cytotoxic drugs. ALDHpos stem cells have been used as resources for regenerative medicine in preclinical models and in an ongoing clinical trial for ischemic cardiomyopathy (clinicatrial.gov, NCT00314366). ALDH1 has been identified as a marker used to isolate cancer stem cells of various human malignancies including bladder, breast, cervical, colon, head and neck, liver, lung, pancreas, prostate, and ovary.
Since these normal and cancer stem cells are very rare, methods to identify and isolate viable, functionally active ALDHpos cells are needed to characterize them. Detectable ALDH substrates reveal those cells in a population that have ALDH activity. Furthermore, because ALDH is a marker of cancer stem cells, compounds that become localized in ALDHpos cells can be used for imaging cancer stem cells and associated tumors in vivo. Compounds that become localized in ALDHpos cells can be used to deliver therapeutic radiation to cancer stem cells (and associated cancers).
SUMMARY
Selection of cells positive for aldehyde dehydrogenase (ALDH) is difficult with existing reagents. Radioactive detectable substrates for ALDH are useful in labeling viable ALDHpos cells. The substrates also can become localized in ALDHpos cancer stem cells, such that the radioactivity is delivered to and localized in the cancer stem cells. A simple radiosynthesis is provided for practical preparation and use of the radioactive substrates.
In one aspect, a detectable substrate for ALDH includes a compound of formula (I):
where X can be O or S: L1 can be a linker moiety; *R can be a radiolabeled moiety; and provided that the compound is not [125I]N-(formylmethyl)-5-iodopyridine-3-carboxamide or [125I]4- (diethylamino)-3-iodobenzaldehyde.
In some aspects, L1 can be a bond; a Ci-Ci0 alkylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl,
cycloalkyl, -OH, -O-alkyl, nitro, cyano, aryl, or heteroaryl, and optionally interrupted by one to three groups individually selected from -0-, -S-, -C(O)-, C(S)-, -N(Ra)-, and -C(0)N(Ra)-; or a Ci-Cio alkenylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro, cyano, aryl, or heteroaryl, and optionally interrupted by one to three groups individually selected from -0-, - S-, -C(O)-, -C(S)-, -N(Ra)-, and -C(0)N(Ra)-; wherein each Ra, individually, can be H, alkyl, or aryl.
*R can have the formula:
where each R2, individually, can be H, halogen, -OH, nitro, cyano, alkyl, -O-alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted by one to five substitutents independently selected from H, halogen, -OH, nitro, cyano, alkyl, -O-alkyl,
alkenyl, or R3; a can be 0, 1 , 2, 3, 4, or 5; L2 can be: (a) a bond; (b) a Ci-Cio alkylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro, cyano, aryl, or heteroaryl and optionally interrupted by one to three group individually selected from -0-, -S-, -C(O)-, -C(S)-, -N(Ra)-, and -C(0)N(Ra)-; (c) a Ci-Cio alkenylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro, cyano, aryl, or heteroaryl, and optionally interrupted by one to three groups individually selected from -0-, -SO-, -C(O)-, -C(S)-, -N(Ra)-, and -C(0)N(Ra)-; or (d) a C6_io arylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro, cyano, aryl, or heteroaryl; where each Ra, individually, can be H, alkyl, or aryl; each R3, independently, can be a radioisotope; and b can be 1 , 2, 3, 4, or 5.
In some embodiments, Ar can be monocyclic aryl or heteroaryl; a can be 0 or 1 ; b can be 1 ; and L2 can be a bond. Each R3, independently, can be 18F, 1231, 1241, 1251, 1261, 1311, 75Br, 76Br, 77Br, 80Br, 80mBr, 82Br, 83Br or 211At. L1 can be a bond or a Ci-Cio alkylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro, cyano, aryl, or heteroaryl, and optionally interrupted by one to three groups individually selected from -0-, -S-, -C(O)-, -C(S)-, -N(Ra)- , and -C(0)N(Ra)-.
In another aspect, a detectable substrate for ALDH includes a compound having the formula:
where each R3, independently, is a radioisotope, and b is 1 , 2, 3, 4, or 5.;
In some aspects, R3 can be 125I and b can be 1 and the detectable substrate can have the formula:
In another aspect, a method of distinguishing ALDH-expressing cells in a population of cells includes exposing the population of cells to a detectable substrate for ALDH as described hereinabove; measuring radioactivity from the cells; and identifying cells exhibiting increased radioactivity from the detectable substrate.
In some aspects, the method can further include, prior to measuring radioactivity from the cells: converting the detectable substrate to the corresponding carboxylic acid within cells expressing ALDH; and retaining and accumulating the corresponding carboxylic acid within cells expressing ALDH. Measuring radioactivity from the cells can include gamma counting, PET, or SPECT.
The population of cells can be exposed to the detectable substrate in the presence of a multi-drug efflux pump inhibitor with dual inhibitory action against ABCB1 and ABCG2. Exposing the population of cells to the detectable substrate can include administering the detectable substrate to a subject. The subject can be a mammal.
In another aspect, a method of treating tumor includes administering a therapeutically effective amount of a compound as described above, where R includes a therapeutically effective radioisotope.
Certain aspects of the presently disclosed subject matter having been stated hereinabove, which are addressed in whole or in part by the presently disclosed subject matter, other aspects will become evident as the description proceeds when taken in connection with the accompanying Examples and Figures as best described herein below.
BRIEF DESCRIPTION OF THE FIGURES
Having thus described the presently disclosed subject matter in general terms, reference will now be made to the accompanying Figures, which are not necessarily drawn to scale, and wherein:
FIG. 1 shows radio-uptake assay of 125IBz-A with K562 and L1210/cpa cells. The x- axis represents cell lines and treatments. The y-axis represents radioactivity (CPM). CPM: counts per minute, DEAB: diethylaminobenzaldehyde; and
FIG. 2 is a radiochromatogram of [125] IBz-A.
DETAILED DESCRIPTION
The presently disclosed subject matter now will be described more fully hereinafter with reference to the accompanying Figures, in which some, but not all embodiments of the presently disclosed subject matter are shown. Like numbers refer to like elements throughout. The presently disclosed subject matter may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. Indeed, many modifications and other embodiments of the presently disclosed subject matter set forth herein will come to mind to one skilled in the art to which the presently disclosed subject matter pertains having the benefit of the teachings presented in the foregoing descriptions and the associated Figures. Therefore, it is to be understood that the presently disclosed subject matter is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims.
ALDH has been studied as a marker for normal and cancer stem cells. For example,
ALDH1 has been identified as a marker used to isolate cancer stem cells of various human malignancies including bladder, breast, cervical, colon, head and neck, liver, lung, pancreas, prostate, and ovary. (I. Ma and A. L. Allan, Stem Cell Rev 7 (2), 292 (2011), which is incorporated by reference in its entirety). For example, Aldhlal and Aldh3al have been implicated in the protection of stem cells from cytotoxic drugs. ALDHpos stem cells have been used as resources for regenerative (see, e.g., A. E. Balber, Stem Cells 29 (4), 570 (2011), which is incorporated by reference in its entirety). Furthermore, the presence of ALDHint leukemic stem cells can be used as a predictor for relapse after therapy J. M.
Gerber, B. D. Smith, B. Ngwang et al, Blood 119 (15), 3571 (2012), which is incorporated by reference in its entirety.
Detectable ALDH substrates allow those cells expressing ALDH (e.g., certain types of stem cells) in a mixed population to be distinguished from those cells that do not express ALDH. One approach is to use a compound having a detectable fluorescent moiety linked to an aldehyde group; the aldehyde group serves as a substrate for ALDH. See, for example, U.S. Patent Nos. 5,876,956, and 6,991,897, each of which is incorporated by reference in its entirety. Another approach is to use a radiolabeled substrate. See, for example,
Vaidyanathan, G., et al., "Targeting aldehyde dehydrogenase: a potential approach for cell labeling," Nuclear Medicine and Biology 36 (2009), 919-929, which is incorporated by reference in its entirety. Both of these approaches rely on a cell-permeable aldehyde substrate being converted to a non-cell permeable carboxylic acid form. When the converted carboxylic acid form is not cell-permeable, the product, with detectable moiety, accumulates in ALDHpos cells. A related approach involves a radiolabeled compound that shows better uptake by ALDH-expressing cells than by other cells (but is not a substrate of ALDH) and accumulates in ALDHpos cells. See, e.g., Chin, B.B., et al., "Synthesis and Preliminary Evaluation of n.c.a. Iodoquine: A Novel Radiotracer with High Uptake in Cells with High ALDH1 Expression," Current Radiopharmaceuticals 5 (2012), 47-58, which is incorporated by reference in its entirety. In some cases, the substrate also can allow cells that express ALDH to a high degree to be distinguished from cells that express it to a smaller degree.
The substrates can be used in a method for identifying intact, viable cells within a cell mixture that express an intracellular marker, for instance an enzyme such as cytosolic ALDH. The intracellular marker reacts with a cell-permeable labeled aldehyde to render the labeled substrate polar (i.e., where the aldehyde is converted to the corresponding carboxylic acid), and, hence, non-permeable to the cell membrane.
Accordingly, a method of detecting ALDHpos cells includes contacting a cell mixture with a cell-permeable, non-polar labeled aldehyde-containing substrate that is rendered polar by contact with the intracellular marker, for instance by oxidation. Once rendered polar, the labeled substrate is no longer permeable to the cell membrane and, hence, is trapped within only those cells in the cell mixture that express the intracellular marker. Cells containing the trapped polar, non-permeable labeled substrate are identified using methods and equipment of detecting radioactivity known to those of skill in the art.
The extent to which the substrate accumulates within a given cell can be related to the extent to which that cell expresses ALDH. All other things being equal, a cell expressing more ALDH will accumulate more.
The method for identifying cells containing cytosolic ALDH in intact, viable cells can provide a cell population enriched in hematopoietic stem cells, preferably a cell suspension of pluripotent hematopoietic stem cells (pluripotent HSCs), that is substantially free of lineage-committed cells. By definition "pluripotent" hematopoietic stem cells are those stem
cells having the ability to repopulate all hematopoietic lineages on a long-term basis. Further discussion of isolation of pluripotent can be found, for example, in US Patent Nos. 5,876,956 and 6,991,897; and in M. Rovira, S. G. Scott, A. S. Liss et al, Proc Natl Acad Sci USA 96, 9118-9123; and Ma and A. L. Allan, Stem Cell Rev 7 (2), 292 (2011); each of which is incorporated by reference in its entirety.
Accordingly, there is a need for detectable ALDH substrates, including detectable ALDH substrates suitable for in vivo imaging of ALDHpos cells.
A compound of formula (I) can serve as a detectable substrate for ALDH:
where X is O or S; L is a linker moiety; and R is a radiolabeled moiety. The radiolabeled moiety includes one or more radioisotopes. Specific exemplary radioisotopes include 18F, 123I, 124I, 125I, 126I, 131I, 75Br, 76Br, 77Br, 80Br, 80mBr, 82Br, 83Br and 211At. Radioisotope- containing compounds can be prepared with sufficient radiolabel to be used in imaging applications. In other words, the compounds can be prepared with radioisotope
concentrations greater than natural abundance, when a particular radioisotope occurs naturally.
When exposed to ALDH, the detectable substrate is converted to the corresponding carboxylic acid of formula (II):
where X, L and R as defined as above. While the compound of formula (I) is desirably cell-permeable, the compound of formula (II) is desirably non-cell permeable.
In some cases, L1 can be a bond; a Ci-Ci0 alkylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, - O-alkyl, nitro, cyano, aryl, or heteroaryl, and optionally interrupted by one to three groups individually selected from -0-, -S-, -C(O)-, -C(S)-, -N(Ra)-, and -C(0)N(Ra)-; or a Ci-Cio alkenylene moiety optionally substituted with from one to five substituents individually
selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro, cyano, aryl, or heteroaryl, and optionally interrupted by one to three groups individually selected from -0-, -S-, -C(O)-, -C(S)-, -N(Ra)-, and -C(0)N(Ra)-; wherein each Ra, individually, is H, alkyl, or aryl.
In some cases, R has the formula:
where each R2, individually, can be H, halogen, -OH, nitro, cyano, alkyl, -O-alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, where each of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl can be optionally substituted by one to five substituents independently selected from H, halogen, -OH, nitro, cyano, alkyl, -O-alkyl, alkenyl, or R3 can be 0, 1, 2, 3, 4, or 5.
L2 can be a bond;
a Ci-Cio alkylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O- alkyl, nitro, cyano, aryl, or heteroaryl, and optionally interrupted by one to three groups individually selected
from-O-, -S-,
-C(O)-, -C(S)-, -N(Ra)-, and -C(0)N(Ra)-;
a Ci-Cio alkenylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro, cyano, aryl, or heteroaryl, and optionally interrupted by one to three groups individually selected from -0-, - S-, -C(O)-, -C(S)-, -N(Ra)-, and -C(0)N(Ra)-; or
a C6-Cio arylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro, cyano, aryl, or heteroaryl;
where each Ra, individually, is H, alkyl, or aryl.
Each R3 can be a radioisotope, b can be 1, 2, 3, 4 or 5.
In some embodiments, a detectable substrate can be prepared by providing a precursor having a suitable leaving group, and substituting the leaving group with a desired radioisotope. The precursor can have a protecting group in place of the aldehyde moiety; for
example, the aldehyde can be protected in the form of an acetal. After the leaving group has been replaced with the desired radioisotope, the acetal can be converted to corresponding aldehyde, affording the detectable substrate. For example, a detectable substrate can be repared according to the following general scheme:
In some cases, for example, when L2 is a bond, Lg is -Sn(alkyl)3, then a suitable salt
3 3 3 125
R " can be used to install the R radioisotope. Some suitable R salts include: Na[ I], Na Na[123I], Na[124I], K[18F], Na[76Br], Na[75Br], Na[211At].
In some embodiments, the detectable substrate has the formula:
where each R3 is a radioisotope, and b is 1, 2, 3, 4, or 5.
The term "alkyl" used alone or as part of a larger moiety (i.e. "alkoxy,"
"hydroxyalkyl," "alkoxyalkyl," and "alkoxycarbonyl") includes both straight and branched chains containing one to ten carbon atoms (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms). Examples of alkyl groups include methyl (Me), ethyl (Et), propyl (Pr) (including n-propyl (nPr or n-Pr), isopropyl ('Pr or i-Pr), butyl (Bu) (including n-pentyl) (nBu or n-Bu), isobutyl (¾u or i-Bu), and tert-butyl (lBu or t-Bu)), pentyl (Pe) (including n-pentyl) and so forth. An alkyl group may be optionally substituted by 1 one 6 substituents selected from halo, hydroxyl,
thiol, oxo, amino, alkylamino, dialkylamino, cyano, nitro, alkyl, alkoxy, alkenyl, alknyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
The term "alkenyl" used along or as part of a larger moiety includes both straight and branched chains containing at least one double bond and two to ten carbon atoms (i.e., 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms), as well as cyclic, non-aromatic alkenyl groups, such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl,
cyclohexadienyl, and the like. As used herein, alkenyl groups also include mixed cyclic and linear alkyl groups, such as cyclopentenylmethyl, cyclopentenylethyl, cyclohexenylmethyl, and the like, so long as the total number of carbon atoms is not exceeded. When the total number of carbons allows (i.e., more than 4 carbons), an alkenyl group may have multiple double bonds, whether conjugated or non-conjugated, but do not include aromatic structures. Examples of alkenyl groups include ethenyl, propenyl, butenyl, butadienyl, isoprenyl, dimethylallyl, geranyl and so forth. An alkenyl group may be optionally substituted by 1 one 6 substituents selected from halo, hydroxyl, thiol, oxo, amino, alkylamino, dialkylamino, cyano, nitro, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
The term "alkynyl" used alone or as part of a larger moiety includes straight and branched chains groups containing at least one triple bond and two to ten carbon atoms (i.e., 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms). When the total number of carbon atoms allows (i.e., more than 4 carbons), an alkynyl group may have multiple triple bonds, whether conjugated or non-conjugated, but do not include aromatic structures. An alkynyl group can include more than one type of multiple bond, i.e., an alkynyl group can include one or more double bonds in addition to at least one triple bond. Examples of alkenyl groups include ethynyl, propynyl, but-2-yn-yl, but-3-ynyl, and so on. An alkynyl group may be optionally substituted by 1 one 6 substituents selected from halo, hydroxyl, thiol, oxo, amino, alkylamino, dialkylamino, cyano, nitro, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl. The term "cycloalkyl" includes mono-, bi-, or tricyclic non- aromatic carbocyclic ring systems having from 3 to 14 ring carbons, and optionally one or more double bonds. The ring systems may be fused, bridged, or spiro ring systems, or a combination of these. Examples of cycloalkyl groups include saturated monocyclic groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like; unsaturated monocyclic groups such as cyclopentenyl,
cyclohexenyl, cycloheptenyl, cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, cyclooctatetraenyl, and the like. Examples of cycloalkyl groups also include saturated bicyclic groups such as decahydronaphthalene, bicycle[3.1.1] heptyl, norbornane, bicyclo[2.2.2]octyl, and the like; unsaturated bicyclic groups such as norbornenyl, bicyclo[2.2.2]oct-2-enyl, and the like. Examples cycloalkyl groups also include saturated tricyclic groups such as tetradecahydroanthracene, tetradecachydrophenanthrene, dodecahydro-s-indacene, and the like, and unsaturated tricyclic groups. Also included within the scope of the term "cycloalkyl" are spiro ring systems, such as spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl, spiro[4.6]undecyl, and the like. Also included within the scope of the term "cycloalkyl" is a group in which a non-aromatic carbocyclic ring is fused to one or more aromatic or non-aromatic rings, such as in a tetrahydronaphthyl or indanyl group, where the radical or point of attachment is on the non-aromatic carbocyclic ring. A cycloalkyl group may be optionally substituted by 1 one 6 substituents selected from halo, hydroxyl, thiol, oxo, amino, alkylamino, dialkylamino, cyano, nitro, alkyl, alkoxy, alkenyl, alkenyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
The term "heterocycle", "heterocyclyl", or "heterocyclic" unless otherwise indicated includes mono-, bi-, or tricyclic non-aromatic ring systems having five to fourteen members, preferably five to ten, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, or S. Examples of heterocyclic groups include 3-1H- benzimidazol-2-one, (l-substituted)-2-oxo-benzimidazol-3-yl, 2-tetrahydrofuranyl, 3- tetrahydrofuranyl, 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl, [1,2]- dioxalanyl, [l,3]-dithiolanyl, [l,3]-dioxanyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 2-thiomorpholinyl, 3-thiomorpholinyl, 4- thiomorpholinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 4-thiazolidinyl, diazolonyl, N- substituted diazolonyl, 1-phthalimidinyl, benzoxanyl, benzopyrrolidinyl, benzopiperidinyl, benzoxolanyl, benzothiolanyl, and benzothianyl. Also included within the scope of the term "heterocyclyl" or "heterocyclic", as it is used herein, is a group in which a non-aromatic heteroatom-containing ring is fused to one or more aromatic or non-aromatic rings, such as in an indolinyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point or attachment is on the non-aromatic heteroatom-containing ring. The term "heterocycle",
"heterocyclyl", or "heterocyclic" whether saturated or partially unsaturated, also refers to rings that are optionally substituted.
The term "aryl" used alone or as a part of a larger moiety, refers to mono-, bi-, or tricyclic aromatic hydrocarbon ring systems having five to fourteen members, such as phenyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl. The term "aryl" may be used interchangeably with the term "aryl ring". "Aryl" also includes fused polycyclic aromatic ring systems in which an aromatic ring is fused to one or more rings. Examples include 1- naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl. Also included within the scope of the term "aryl", as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as in an indanyl, phenanthridinyl or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic ring.
The term "heteroaryl", used alone or as part of a larger moiety, refers to
heteroaromatic ring groups having five to fourteen members, preferably five to ten, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, or S. Examples of heteroaryl rings include 2-furanyl, 3-furanyl, N-imidazolyl, 2- imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2- oxadiazolyl, 5-oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 1 -pyrrolyl, 2-pyrrolyl, 3- pyrrolyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 3-pyridazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 5-tetrazolyl, 2- triazolyl, 5-triazolyl, 2-thienyl, 3-thienyl, carbazolyl, benzimidazolyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, benzotriazolyl, benzothiazolyl, benzooxazolyl,
benzimidazolyl, isoquinolinyl, indazolyl, isoindolyl, acridinyl, or benzoisoxazolyl. Also included within the scope of the term "heteroaryl", as it is used herein, is a group in which heteroaromatic ring is fused to one or more aromatic or nonaromatic rings where the radical or point of attachment is on the heteroaromatic ring. Examples include tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[3,4-d]pyrimidinyl. The term "heteroaryl" may be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic."
Compounds of formula (I), in particular various radiolabeled compounds, may be used for diagnostic, imaging, or therapeutic purposes. For example, some compounds, e.g. those labeled with 125I and 123I, can be used for SPECT imaging, while some compounds, e.g. those labeled with 18F and 124I, can be used for PET imaging, and some radioisotopically
labeled compounds may be used therapeutically. In general, the suitability of a particular radioisotope for a particular purpose is well understood in the art. Other exemplary embodiments are compounds used as precursors for radiolabeled compounds, in which a substituent may be directly exchanged for a radioisotope in one or more steps. Unless described otherwise, the terms "converted," "derivatized," "exchanged," or "reacted" are intended to encompass one or more steps. Examples of substituents that may be exchanged for radioisotopes include halogens, -N02, -N+(alkyl)3, -Sn(alkyl)3, -Si(alkyl)3, -Hg(alkyl), and -B(OH)2. Other compounds are precursors which may be chemically reacted with a radioisotopically labeled reagent to produce a stable radioisotopically labeled compound. Compounds bearing substituents such as halogen, -NH2, -NHNH2, -Sn(alkyl)3, and -B(OH)2, for example, may be converted into radioisotopically labeled compounds by chemical reactions known to those in the art.
Other embodiments include methods of imaging one or more cells, organs or tissues, where the method includes exposing cells to, or administering to a subject, an effective amount of a compound with an isotopic label suitable for imaging. In still another embodiment, the imaging method is suitable for imaging of cancer, tumor or neoplasm. In a further embodiment, the cancer is selected from eye or ocular cancer, rectal cancer, colon cancer, cervical cancer, prostate cancer, breast cancer and bladder cancer, oral cancer, benign and malignant tumors, stomach cancer, liver cancer, pancreatic cancer, lung cancer, corpus uteri, ovary cancer, prostate cancer, testicular cancer, renal cancer, brain cancer (e.g., gliomas), throat cancer, skin melanoma, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's Sarcoma, Kaposi's Sarcoma, basal cell carcinoma and squamous cell carcinoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, angiosarcoma, hemangioendothelioma, Wilms Tumor, neuroblastoma, mouth/pharynx cancer, esophageal cancer, larynx cancer, lymphoma, neurofibromatosis, tuberous sclerosis, hemangiomas, and lymphangiogenesis.
The imaging methods are suitable for imaging any physiological process or feature in which ALDH is involved. Typically, imaging methods are suitable for identification of areas of tissues or targets which express high concentrations of ALDH. In certain embodiments, the radiolabeled compound is detected by positron emission tomography (PET) or single photon emission computed tomography (SPECT).
The subject in the imaging method is a human, rat, mouse, cat, dog, horse, sheep, cow, monkey, avian, or amphibian. Typical subjects to which compounds of the invention may be administered will be mammals, particularly primates, especially humans. For veterinary applications, a wide variety of subjects will be suitable, e. g. livestock such as cattle, sheep, goats, cows, swine and the like; poultry such as chickens, ducks, geese, turkeys, and the like; and domesticated animals particularly pets such as dogs and cats. For diagnostic or research applications, a wide variety of mammals will be suitable subjects including rodents (e.g. mice, rats, hamsters), rabbits, primates, and swine such as inbred pigs and the like. Additionally, for in vitro applications, such as in vitro diagnostic and research applications, body fluids and cell samples of the above subjects will be suitable for use such as mammalian, particularly primate such as human, blood, urine or tissue samples, or blood urine or tissue samples of the animals mentioned for veterinary applications. The body fluids and cell samples of the above subjects can be in vivo or in vitro.
In certain of the presently disclosed methods, the compounds of the invention are excreted from tissues of the body quickly to prevent prolonged exposure to the radiation of the radiolabeled compound administered to the patient. Typically compounds of the invention are eliminated from the body in less than about 24 hours. More typically, compounds of the invention are eliminated from the body in less than about 16 hours, 12 hours, 8 hours, 6 hours, 4 hours, 2 hours, 90 minutes, or 60 minutes. Exemplary compounds are eliminated in between about 60 minutes and about 120 minutes.
Other embodiments provide methods of treating tumors comprising administering to a subject a therapeutically effective amount of a compound of formula (I) comprising a therapeutically effective radioisotope. In certain embodiments, the tumor cells may express ALDH. In other embodiments, a tumor may be treated by targeting adjacent or nearby cells which express ALDH. Examples of therapeutically effective radioisotopes include 13 T and 211At.
Stem cells generally express one or more active multi-drug efflux pumps, such as ABCB1 and/or ABCG2. The detectable ALDH substrate may also be a substrate for those pumps. Thus, even though ALDH substrates are converted into polar form (e.g., carboxylic acid form), the pumps can remove the converted ALDH from the cell, contrary to the desired accumulation of the converted ALDH substrate within ALDHpos cells. It can therefore be
desirable, when assaying cells for ALDH activity, to include an inhibitor of one or more multi-drug efflux pumps. For example, the commercial Aldefluor® assay buffer contains verapamil, a pump inhibitor (see also U.S. Patent No. 6,991,897, which is incorporated by reference in its entirety). Verapamil is an inhibitor of ABCB1, but does not inhibit ABCG2. Even in the presence of verapamil, cells that do accumulate the converted substrate can exhibit gradual decrease of fluorescent intensity over time (e.g., on the order of 1 hour). Inhibiting both pumps can enhance the accumulation of the converted inhibitor in ALDHpos cells, so that identification of ALDHpos cells is more effective than when no inhibitor, or an inhibitor of only one pump, is present.
Therefore it can be advantageous to carry out assays for ALDHpos cells in the presence of an inhibitor of ABCB1, and inhibitor of ABCG2, or more preferably in the presence of both an inhibitor of ABCB1 and an inhibitor of ABCG2, or more preferably in the presence of a dual-activity inhibitor of ABCB1 and ABCG2, i.e., a single compound that inhibits both ABCB1 and ABCG2. Inhibitors of ABCB1, including verapamil, are known. Some inhibitors of ABCG2 are
described in, for example, Zhang, Y., et al, Cancer Res. 2009; 69 (14), 5867-5875, which is incorporated by reference in its entirety. Dual action inhibitors, i.e., that inhibit both ABCB1 and ABCG2, include Galfenine, doxazosin mesylate, clebopride maleate, and flavoxate hydrochloride. Inhibitors of ABCG2 (but not ABCB1) include: fumitremorgin C (FTC), Kol43, Gefitinib, Harmine, Prazosin, Dipyridamole, Curcumin, Nelfmavir mesylate, Niguldipine, Riboflavin, Reserpine, Hesperetin, Tracazolate, Verteporfm, Quinacrine, Metyrapone, Rotenone, Acepromazine, Flutamide, Podophyllum resin, Piperacetazine, Acetophenazine maleate, and Raloxifme hydrochloride.
Other embodiments provide kits comprising a compound of formula (I). In certain embodiments, the kit provides packaged pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a compound of formula (I). In certain embodiments the packaged pharmaceutical composition will include the reaction precursors necessary to generate the compound of formula (I) upon combination with a radiolabeled precursor.
Other packaged pharmaceutical compositions further include indicia comprising at least one of: instructions for preparing compounds according to the invention from supplied precursors, instructions for using the composition to image cells or tissues expressing ALDH.
In certain embodiments, a kit according to the invention contains from about 1 to about 30 mCi of the radionuclide-labeled compound described above, in combination with a pharmaceutically acceptable carrier. The compound and carrier may be provided in solution or in lyophilized form. When the compound and carrier of the kit are in lyophilized form, the kit may optionally contain a sterile and physiologically acceptable reconstitution medium such as water, saline, buffered saline, and the like. The kit may provide a compound in solution or in lyophilized form, and these components of the kit may optionally contain stabilizers such as NaCl, silicate, phosphate buffers, ascorbic acid, gentisic acid, and the like. Additional stabilization of kit components may be provided in this embodiment, for example, by providing the reducing agent in an oxidation-resistant form. Determination and optimization of such stabilizers and stabilization methods are well within the level of skill in the art.
In certain embodiments, a kit provides a non-radiolabeled precursor to be combined with a radiolabeled reagent on-site. Examples of radioactive reagents include Na[125I], Na[131I], Na[123I], Na[124I], K[18F], Na[76Br], Na[75Br], Na[211At].
Imaging agents may be used to generate images by virtue of differences in the spatial distribution of the imaging agents which accumulate at a site when contacted with converted to polar form by ALDH. The spatial distribution may be measured using any means suitable for the particular label, for example, a gamma camera, a PET apparatus, a SPECT apparatus, and the like. The extent of accumulation of the imaging agent may be quantified using known methods for quantifying radioactive emissions.
In general, a detectably effective amount of the imaging agent of the invention is administered to a subject. In accordance with the invention, "a detectably effective amount" of the imaging agent of the invention is defined as an amount sufficient to yield an acceptable image using equipment which is available for clinical use. A detectably effective amount of the imaging agent of the invention may be administered in more than one injection. The detectably effective amount of the imaging agent of the invention can vary according to factors such as the degree of susceptibility of the individual, the age, sex, and weight of the individual, idiosyncratic responses of the individual, and the dosimetry. Detectably effective amounts of the imaging agent of the invention can also vary according to instrument and film-related factors. Optimization of such factors is well within the level of skill in the art.
The amount of imaging agent used for diagnostic purposes and the duration of the imaging study will depend upon the radionuclide used to label the agent, the body mass of the patient, the nature and severity of the condition being treated, the nature of therapeutic treatments which the patient has undergone, and on the idiosyncratic responses of the patient.
Ultimately, the attending physician will decide the amount of the imaging agent to administer to each individual patient and the duration of the imaging study.
A "pharmaceutically acceptable carrier" refers to a biocompatible solution, having due regard to sterility, p[Eta], isotonicity, stability, and the like and can include any and all solvents, diluents (including sterile saline, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection and other aqueous buffer solutions), dispersion media, coatings, antibacterial, and antifungal agents, isotonic agents, and the like. The pharmaceutically acceptable carrier may also contain stabilizers, preservatives, antioxidants, or other additives, which are well known to one of skill in the art, or other vehicle as known in the art.
As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making non-oxic acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, malefic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonix, oxalic, isethionic, HOOC-(CH2)n- COOH where n is 0, 1, 2, 3, or 4, and the like. The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound that contains a basic or acidic moiety by
conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na,
Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used, where practicable. Lists of additional suitable salts may be found, e.g., in Remington's
Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, p. 1418 (1985).
Following long-standing patent law convention, the terms "a," "an," and "the" refer to "one or more" when used in this application, including the claims. Thus, for example, reference to "a subject" includes a plurality of subjects, unless the context clearly is to the contrary (e.g., a plurality of subjects), and so forth.
Throughout this specification and the claims, the terms "comprise," "comprises," and "comprising" are used in a non-exclusive sense, except where the context requires otherwise. Likewise, the term "include" and its grammatical variants are intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that can be substituted or added to the listed items.
For the purposes of this specification and appended claims, unless otherwise indicated, all numbers expressing amounts, sizes, dimensions, proportions, shapes, formulations, parameters, percentages, parameters, quantities, characteristics, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term "about" even though the term "about" may not expressly appear with the value, amount or range. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are not and need not be exact, but may be approximate and/or larger or smaller as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors known to those of skill in the art depending on the desired properties sought to be obtained by the presently disclosed subject matter. For example, the term "about," when referring to a value can be meant to encompass variations of, in some embodiments, ± 100% in some
embodiments ± 50%, in some embodiments ± 20%>, in some embodiments ± 10%>, in some embodiments ± 5%, in some embodiments ±1%, in some embodiments ± 0.5%>, and in some embodiments ± 0.1% from the specified amount, as such variations are appropriate to perform the disclosed methods or employ the disclosed compositions.
Further, the term "about" when used in connection with one or more numbers or numerical ranges, should be understood to refer to all such numbers, including all numbers in a range and modifies that range by extending the boundaries above and below the numerical values set forth. The recitation of numerical ranges by endpoints includes all numbers, e.g., whole integers, including fractions thereof, subsumed within that range (for example, the recitation of 1 to 5 includes 1, 2, 3, 4, and 5, as well as fractions thereof, e.g., 1.5, 2.25, 3.75, 4.1, and the like) and any range within that range.
EXAMPLES
The following Examples have been included to provide guidance to one of ordinary skill in the art for practicing representative embodiments of the presently disclosed subject matter. In light of the present disclosure and the general level of skill in the art, those of skill can appreciate that the following Examples are intended to be exemplary only and that numerous changes, modifications, and alterations can be employed without departing from the scope of the presently disclosed subject matter. The synthetic descriptions and specific examples that follow are only intended for the purposes of illustration, and are not to be construed as limiting in any manner to make compounds of the disclosure by other methods.
Example 1
Methods and Materials
Cell Lines. The K562 human chronic myelogenous leukemia cell line was purchased from American Type Culture Collection (CLL-243™) and maintained in suspension in IMDM media supplemented with 10% FBS. The murine leukemia cell line L1210
(ALDHl0W) and L1210/cpa (ALDHhi) were provided by Dr. Richard J. Jones (Johns Hopkins University) and maintained in suspension in RPMI 1640 supplemented with 10% FBS.
Human glioma cell line, U87-tri was provided by Dr. John Laterra (Kennedy Krieger Institute) and maintained in DMEM media supplemented with 10% FBS. All cells were grown at 37°C in a humidified incubator with 5% C02.
Reagents and analyses. Chemicals and solvents obtained from commercial sources were analytical grade or better and used without further purification. Sodium Iodide- 125
(Na125I) was obtained as a 0.1 N solution of NaOH (high concentration) from MP Biomedical
(Solon, Ohio). Analytical thin-layer chromatography (TLC) was performed using Aldrich aluminum backed 0.2 mm silica gel plates and visualized by UV light (254nm) and I2. Flash column chromatography was performed on silica gel (60 A, MP Biomedicals). Radio-HPLC purification was performed using a Waters (Milford, MA) system equipped with two Waters 510 pumps, a Waters 490E variable wavelength UV/Vis detector set at 254 nm, a BioScan FlowCount radioactivity detector, a Waters radial-PAK CI 8 reverse phase analytical column (8 100 mm) with H20/CH3CN/TFA solvent systems, and Win Flow (LabLogic) chromatography software. 1H NMR was recorded on a Bruker (Billerica, MA) Ultrashield™ 400 MHz spectrometer. ESI mass spectra were obtained with a Bruker Daltonics Esquire 300 plus spectrometer. Radioactivity was measured in a Capintec CRC-12 dose calibrator.
EXAMPLE 2
Synthesis of ALDH substrates
IBz aldehyde diethyl acetal (IBz-A-DA). To 50 mg (0.15 mmol) of N-succinimidyl 4- iodobenzoate in 2 mL of tetrahydrofuran (THF) was added 38 mg of aminoaldehyde diethyl acetal (0.3 mmol) and 50 of NEt3 and stirred at room temperature for 1 hr. IBz-A- DA was purified by flash column chromatography using 2: 1 hexane/ethyl acetate to give IBz-A-DA 1 (Rf=0.3, 47 mg, 90% yield). 1H NMR (CDC13) 1.21 (t, 6H, J=6.8 hz), 3.55(m, 4H), 3.72(m, 2H), 4.59(dd, 1H, J=6hz, 4.8hz), 6.33(br, 1H), 7.47(d, 2H, J=7.6Hz), 7.76(d, 2H, J=7.6Hz).
The synthesis of IBz-A-DA and IBz-A is provided in Scheme 1.
Scheme 1
IBz aldehyde (IBz-A). To 15 mg of IBz-A-DA was added 0.5 mL of CH2C12 was added 0.5 mL of TFA. After 0.5 hour reaction, TLC showed that all starting materials were disappeared. Reaction solvent was removed in vacuo and IBz-A was purified by flash
column chromatography using 1 : 1 hexane/ethyl acetate to give IBz-A 2 (Rf=0.35, 5.3 mg, 45% yield). 1H NMR (CDC13) 4.45(s, 2H), 6.86(br, 1H), 7.57(d, 2H, J=8HZ), 7.84(d, 2H, J=8Hz), 9.81(s, 1H).
SnBz aldehyde diethyl acetal (SnBz-A-DA). To 32 mg of N-succinimidyl 4-(tri-n- butylstannyl)benzoate (0.062 mmol) in 1 mL of THF was added 17 mg of aminoaldehyde diethyl acetal (0.126 mmol) and 50 of Net3 and stirred at room temperature for 1 hr. Then SnBz-A-DA was purified by flash column chromatography using 3 : 1 hexane/ethyl acetate to give SnBz-A-DA 3 (¾=0.25, 30 mg, 66% yield).
EXAMPLE 3
Radiosvnthesis of 125I-IBz-A-DA
To a 1 mL v-vial was added 50 μΐ^ of SnBz-A-DA in MeOH (lmL/min) and 10 of NCS in water (lmg/mL) and 10 of water, 9.8 mCi of I125-Nal was then added. The reaction mixture was incubated at room temperature for 25 minutes, and injected into HPLC for purification. HPLC condition is 70/30 water/acetonitrile with flow rate at lmL/min on a waters radial Pak CI 8 analytical column. The fraction at retention time of 22 minutes is collected to give 125I- IBz-A-DA (8.3 mCi, 84%RCY, Specific activity: 2000 mCi/μιηοΙ). Radioiodination of tin precursor SnBz-A-DA yielded the acetal intermediate [125] IBz-A-DA in about 85% radiochemical yield.
The synthesis of 125IBz-A-DA and 125IBz-A is provided in Scheme 2. Alternative conditions for the synthesis of IBz-A-DA, and IBz-A, 125IBz-A-DA, and 125IBz-A are provided in Scheme 3.
Scheme 2
125IBz-A
Scheme 3
EXAMPLE 4
Preparation of Aldehyde Forms of the Presently Disclosed Agents 125IBz-A-DA was dissolved in 100% DMSO at 10 mCi/50 μΕ concentration and stored at -20 °C as stock solutions. 25 of a stock was deprotected by mixing with the same volume of 2N HCl for 30 mins at room temperature and the resulting aldehyde (IBz-A) were neutralized by adding 350 of the assay buffer (PBS supplemented with 1% FBS and 50 μΜ Verapamil, Sigma V4629) and immediately used.
EXAMPLE 5
In Vitro Radio Uptake Assay for ALDH Activity
One million cells were resuspended in the assay buffer and 1 μθ of IBz-A (with or without 1000 fold cold competitor) was added to the cell. A 0.5-mL aliquot of cells was immediately taken and added to a tube containing 5μΙ^ of DEAB (Stem Cell Technologies, 01705). Cells were incubated in 37 °C water bath for 30 mins and washed with 4 mL of the cold assay buffer. Cells were resuspended in the cold assay buffer (5 x 105/200μΕ) and
stored in the ice until analyzed. Cells were washed twice with cold assay buffer and the radioactivity was measured by LKB Wallac gamma counter (1282 compugamma CS).
EXAMPLE 5
Results and Discussion
125IBz-A was tested for specific uptake by ALDH-expressing cell lines (K562 and L1210/cpa). When compared with cells treated with DEAB (ALDH inhibitor), both cells showed more than 5-fold increase of uptake (Fig. 1). This increase in uptake indicates 125IBz-A is a specific substrate of ALDH and can be used to label live cells that express ALDH.
Although the foregoing subject matter has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be understood by those skilled in the art that certain changes and modifications can be practiced within the scope of the appended claims.
Claims
1. A detectable substrate for ALDH comprising a compound of formula (I):
wherein X is O or S; L1 is a linker moiety;
*R is a radiolabeled moiety;
provided that the compound is not [125I]N-(formylmethyl)-5-iodopyridine-3- carboxamide or [125I]4-(diethylamino)-3-iodobenzaldehyde.
2. The detectable substrate of claim 1, wherein L1 is a bond; a Ci-Cio alkylene moiety optionally substituted with form one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro, cyano, aryl, or heteroaryl, and optionally interrupted by one to three groups individually selected from -0-, -S-, -C(O)-, -C(S)-, -N(Ra)- , and -C(0)N(Ra)-; or a Ci-Cio alkenylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro, cyano, aryl, or heteroaryl, and optionally interrupted by one to three groups
individually selected from -0-, -S-, -C(0)-, -C(S)-, -N(Ra)-, and -C(0)N(Ra)-; wherein each Ra, individually, is H, alkyl, or aryl.
3. The detectable substrate of claim 1, wherein *R has the formula:
wherein
each R2, individually, is H, halogen, -OH, nitro, cyano, alkyl, -O-alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted by one to five
substituents independently selected from H, halogen, -OH, nitro, cyano, alkyl, -O-alkyl, alkenyl, or R3;
a is 0, 1, 2, 3, 4, or 5;
L2 is :
(a) a bond;
(b) a Ci-Cio alkylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro cyano, aryl, or heteroaryl, and optionally interrupted by one to three groups individually selected from -0-, - S-, -C(O)-, -C(S)-, -N(Ra)-, and -C(0)N(Ra)-;
(c) a Ci-Cio alkenylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro cyano, aryl, or heteroaryl, and optionally interrupted by one to three groups individually selected from -0-, -S-, -C(O)-, -C(S)-, -N(Ra)-, and -C(0)N(Ra)-; or
(d) a Ci-Cio arylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro cyano, aryl, or heteroaryl;
wherein each Ra, individually, is H, alkyl, or aryl;
each R3, independently, is a radioisotope; and
b is 1, 2, 3, 4, or 5.
4. The detectable substrate of claim 3, wherein Ar is monocyclic aryl or heteroaryl; a is 0 or 1 ; b is 1 ; and L2 is a bond.
5. The detectable substrate of any one of claims 3 to 4, wherein each R3, independently, is 18F, 123I, 124I, 125I, 126I, 131I, 75Br, 76Br, 77Br, 80Br, 80mBr, 82Br, 83Br or 211At.
6. The detectable substrate of any one of claims 1 to 5, wherein L1 is a bond or a Ci-Cio alkylene moiety optionally substituted with from one to five substituents individually selected from H, halogen, alkyl, cycloalkyl, -OH, -O-alkyl, nitro, cyano, aryl, or heteroaryl, and optionally interrupted by one to three groups individually selected from -O, -S-, -C(O)-, - C(S)-,-N(Ra)-, and -C(0)N(Ra)-.
7. A detectable substrate for ALDH comprising a compound having the formula:
wherein each R3, independently, is a radioisotope, and b is 1, 2, 3, 4, or 5.
8. The detectable substrate of claim 7, wherein R3 is 125I and b is 1.
9. The detectable substrate of claim 8, having the formula:
10. A method for distinguishing ALDH-expressing cells in a population of cells, comprising:
exposing the population of cells to detectable substrate for ALDH of any one of claims 1-9; measuring radioactivity from the cells; and
identifying cells exhibiting increased radioactivity from the detectable substrate.
11. The method of claim 10, further comprising, prior to measuring radioactivity from the cells:
converting the detectable substrate to the corresponding carboxylic acid within cells expressing ALDH; and
retaining and accumulating the corresponding carboxylic acid within cells expressing ALDH.
12. The method of any one of claims 10-11, wherein measuring radioactivity from the cells includes gamma counting, PET, or SPECT.
13. The method of any one of claims 10-12, wherein the population of cells is exposed to the detectable substrate in the presence of a multi-drug efflux pump inhibitor with dual inhibitory action against ABCB1 and ABCG2.
14. The method of any one of claims 10-13, wherein exposing the population of cells to the detectable substrate includes administering the detectable substrate to a subject.
15. The method of claim 14, wherein the subject is a mammal.
16. A method for treating a tumor, comprising administering a therapeutically effective amount of a compound according to any one of claims 1-9, wherein *R includes a therapeutically effective radioisotope.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/777,117 US20160008493A1 (en) | 2013-03-15 | 2014-03-17 | Radioactive substrates for aldehyde dehydrogenase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791272P | 2013-03-15 | 2013-03-15 | |
US61/791,272 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014145493A1 true WO2014145493A1 (en) | 2014-09-18 |
Family
ID=51538013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/030274 WO2014145493A1 (en) | 2013-03-15 | 2014-03-17 | Radioactive substrates for aldehyde dehydrogenase |
Country Status (2)
Country | Link |
---|---|
US (1) | US20160008493A1 (en) |
WO (1) | WO2014145493A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200008942A (en) * | 2018-07-17 | 2020-01-29 | 한국원자력연구원 | Method for labeling radioisotope, radiolabeled compounds and kit comprising the same for labeling radioisotope |
US11298431B2 (en) | 2018-07-17 | 2022-04-12 | Korea Atomic Energy Research Institute | Method for labeling radioisotope radiolabeling compound and kit comprising the same for labeling radioisotope |
US11345681B1 (en) | 2020-06-05 | 2022-05-31 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
WO2022214995A1 (en) * | 2021-04-06 | 2022-10-13 | Universita' Degli Studi Del Piemonte Orientale "A. Avogadro" | Probe directed to enzyme aldh1a3 and use thereof in the diagnosis of glioblastoma |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114262279B (en) * | 2021-12-30 | 2022-12-16 | 上海汇禾医疗科技有限公司 | X-ray developable molecule, embolism microsphere and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060142207A1 (en) * | 2002-03-29 | 2006-06-29 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
US20110286922A1 (en) * | 2008-10-21 | 2011-11-24 | Alan Cuthbertson | Imaging and radiotherapy methods |
WO2013048832A1 (en) * | 2011-09-29 | 2013-04-04 | Ge Healthcare Limited | 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells |
WO2013048811A1 (en) * | 2011-09-30 | 2013-04-04 | Ge Healthcare Limited | Imaging and radiotherapy methods for tumour stem cells |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1975243E (en) * | 1998-12-07 | 2010-06-24 | Univ Duke | Bodipy aminoacetaldehyde diethyl acetal |
US20110250129A1 (en) * | 2008-11-12 | 2011-10-13 | The Johns Hopkins University | Bioluminescence imaging-based screening assay and inhibitors of abcg2 |
-
2014
- 2014-03-17 WO PCT/US2014/030274 patent/WO2014145493A1/en active Application Filing
- 2014-03-17 US US14/777,117 patent/US20160008493A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060142207A1 (en) * | 2002-03-29 | 2006-06-29 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
US20110286922A1 (en) * | 2008-10-21 | 2011-11-24 | Alan Cuthbertson | Imaging and radiotherapy methods |
WO2013048832A1 (en) * | 2011-09-29 | 2013-04-04 | Ge Healthcare Limited | 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells |
WO2013048811A1 (en) * | 2011-09-30 | 2013-04-04 | Ge Healthcare Limited | Imaging and radiotherapy methods for tumour stem cells |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200008942A (en) * | 2018-07-17 | 2020-01-29 | 한국원자력연구원 | Method for labeling radioisotope, radiolabeled compounds and kit comprising the same for labeling radioisotope |
KR102230657B1 (en) * | 2018-07-17 | 2021-03-23 | 한국원자력연구원 | Method for labeling radioisotope, radiolabeled compounds and kit comprising the same for labeling radioisotope |
US11298431B2 (en) | 2018-07-17 | 2022-04-12 | Korea Atomic Energy Research Institute | Method for labeling radioisotope radiolabeling compound and kit comprising the same for labeling radioisotope |
US11345681B1 (en) | 2020-06-05 | 2022-05-31 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
WO2022214995A1 (en) * | 2021-04-06 | 2022-10-13 | Universita' Degli Studi Del Piemonte Orientale "A. Avogadro" | Probe directed to enzyme aldh1a3 and use thereof in the diagnosis of glioblastoma |
Also Published As
Publication number | Publication date |
---|---|
US20160008493A1 (en) | 2016-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220088229A1 (en) | Psma-binding agents and uses thereof | |
US20160008493A1 (en) | Radioactive substrates for aldehyde dehydrogenase | |
JP5349960B2 (en) | Stereoselective synthesis of amino acid analogs for tumor imaging | |
MX2013004834A (en) | Tau imaging probe. | |
AU2008237930A1 (en) | 18F-labelled folates | |
US8168786B2 (en) | Radiolabeled compounds and uses thereof | |
Lindberg et al. | Synthesis and evaluation of two new candidate high-affinity full agonist PET radioligands for imaging 5-HT1B receptors | |
AU2016235483A1 (en) | Organic compounds | |
US20100034741A1 (en) | Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor | |
US9290463B2 (en) | Radiolabeled compounds and uses thereof | |
WO2016005419A1 (en) | 4-oxo-1,4-dihydroquinoline-3-carboxamide as selective ligand for cannabinoid receptor 2 for diagnosis and therapy | |
US20200290976A1 (en) | Radiolabeled microtubule imaging compounds and uses thereof | |
US10421722B2 (en) | Sulfur-containing compounds targeting vesicular acetylcholine transporter | |
WO2015200674A1 (en) | Neuroactive compounds and methods of using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14765600 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14777117 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14765600 Country of ref document: EP Kind code of ref document: A1 |